[Translation] A multicenter clinical trial on the efficacy and safety of Shenlixin granules in the treatment of chronic renal failure stage 4 with spleen-kidney yang deficiency and dampness-stasis syndrome

初步评价肾力欣颗粒治疗脾肾阳虚、湿浊兼有血瘀证慢性肾衰CKD4期的有效性和安全性

[Translation]

Preliminary evaluation of the efficacy and safety of Shenlixin granules in the treatment of chronic renal failure (CKD) stage 4 with spleen and kidney yang deficiency, dampness and blood stasis

Start Date-

Sponsor / Collaborator

Shanghai Yusen New Medicine Development Co.,Ltd.

CTR20130915 / Not yet recruitingPhase 2

肾力欣颗粒治疗脾肾阳虚、湿瘀互结型慢性肾衰CKD4期有效性和安全性的多中心临床试验

初步评价肾力欣颗粒治疗脾肾阳虚、湿浊兼有血瘀证慢性肾衰CKD4期的有效性和安全性

[Translation]

Preliminary evaluation of the efficacy and safety of Shenlixin granules in the treatment of chronic renal failure (CKD) stage 4 with spleen and kidney yang deficiency, dampness and blood stasis

Start Date-

Sponsor / Collaborator

Shanghai Yusen New Medicine Development Co.,Ltd.

CTR20130917 / RecruitingPhase 2

肾力欣颗粒治疗脾肾阳虚、湿瘀互结型慢性肾衰CKD4期有效性和安全性的多中心临床试验

初步评价肾力欣颗粒治疗脾肾阳虚、湿浊兼有血瘀证慢性肾衰CKD4期的有效性和安全性

[Translation]

Preliminary evaluation of the efficacy and safety of Shenlixin granules in the treatment of chronic renal failure (CKD) stage 4 with spleen and kidney yang deficiency, dampness and blood stasis

Start Date21 Nov 2013

Sponsor / Collaborator

Shanghai Yusen New Medicine Development Co.,Ltd.

100 Clinical Results associated with Shenlixin Granules

100 Translational Medicine associated with Shenlixin Granules

100 Patents (Medical) associated with Shenlixin Granules

Literatures (Medical) associated with Shenlixin Granules

29 Jan 2021·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Protective Effects of Shenfuyixin Granule on H2O2-Induced Apoptosis in Neonatal Rat Cardiomyocytes

Q4 · MEDICINE

ArticleOA

Author: Li, Bin ; Xie, Shiyang ; Wang, Youping ; Zhu, Mingjun ; Wang, Xinlu ; Wang, Yongxia ; Hao, Xuanxuan ; Cui, Lin

Shenfuyixin granule (SFYXG, i.e., Xinshuaikang granule) is a prescription, commonly used in the clinical experience, which plays a significant role in the treatment of heart failure. The purpose of this present research was to investigate the protective effect of SFYXG, and the mechanism about anti-H2O2-induced oxidative stress and apoptosis in the neonatal rat cardiomyocytes. Myocardial cells, as is well known, were divided into 4 groups: normal, model, SFYXG, and coenzyme Q10 group, respectively. Cells viability was determined by MTT assay. Flow cytometry and AO/EB staining were implemented to test the apoptosis rate and intracellular reactive oxygen species (ROS) level. Mitochondrion membrane potential (MMP) was evaluated by JC-1 fluorescence probe method. The myocardial ultrastructure of mitochondrion was measured by electron microscope. The related mRNA expression levels of Bax, Bcl-2, Caspase-3, caspase-8, and caspase-9 were detected by real-time polymerase chain reaction (PCR). Also, the expression levels of Bax and Bcl-2 protein were detected by Western blot, and the expression levels of caspase-3, caspase-8, and caspase-9 protein were tested by caspase-Glo®3 Assay, caspase-Glo®8 Assay, and caspase-Glo®9 Assay, respectively. GAPDH was used as the internal reference gene/protein. The results revealed that SFYXG (0.5 mg/ml) raised the viability of myocardial cell, weakened the apoptosis rate and ROS level, corrected the mitochondrion membrane potential stability, and improved cell morphology and ultrastructure of myocardial mitochondrion. Furthermore, SFYXG upregulated the antiapoptosis gene of Bcl-2, but downregulated the proapoptosis genes of Bax, caspase-3, and caspase-9. In conclusion, SFYXG could appear to attenuate myocardial injury by its antioxidative and antiapoptosis effect.

100 Deals associated with Shenlixin Granules

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	CN	Shanghai Yusen New Medicine Development Co.,Ltd.	25 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Shenlixin Granules

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation